Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: 48 Week Efficacy and Safety Results of a Phase II Randomized Placebo-Controlled Multicenter Trial

被引：0
|
作者：
Kappos, Ludwig
Li, David
Calabresi, Peter
O'Connor, Paul
Bar-Or, Amit
Barkhof, Frederik
Yin, Ming
Leppert, David
Glanzman, Robert
Tinbergen, Jeroen
Hauser, Stephen
机构：
来源：
NEUROLOGY | 2011年 / 76卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A545 / A545
页数：1
相关论文
共 50 条
  • [21] A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Safety and Efficacy of Daclizumab HYP Monotherapy in Relapsing-Remitting Multiple Sclerosis: Primary Results of the SELECT Trial
    Gold, Ralf
    Giovannoni, Gavin
    Selmaj, Krzysztof
    Havrdova, Eva
    Montalban, Xavier
    Radue, Ernst-Wilhelm
    Stefoski, Dusan
    Robinson, Randy
    Riester, Katherine
    Elkins, Jacob
    O'Neill, Gilmore
    NEUROLOGY, 2012, 78
  • [22] A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis: primary results of the SELECT trial
    Giovannoni, G.
    Gold, R.
    Selmaj, K.
    Havrdova, E.
    Montalban, X.
    Radue, E. W.
    Stefoski, D.
    Robinson, R.
    Riester, K.
    Elkins, J.
    O'Neill, G.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S508 - S509
  • [23] Placebo-controlled trials in relapsing-remitting multiple sclerosis: are they still needed?
    Waschbisch, Anne
    Derfuss, Tobias
    FUTURE NEUROLOGY, 2012, 7 (01) : 37 - 44
  • [24] The efficacy of cladribine in relapsing-remitting multiple sclerosis: Clinical data from a randomized, double-blind, placebo-controlled, 18-month, phase II trial
    Sipe, Jack
    Gardner, Jason
    Beutler, Ernest
    NEUROLOGY, 2008, 70 (11) : A90 - A91
  • [25] Results of the 48-Week Blinded Extension of RADIANCE: a Randomized, Placebo-controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis
    Cohen, Jeffrey A.
    Selmaj, Krzysztof
    Arnold, Douglas
    Comi, Giancarlo C.
    Bar-Or, Amit
    Gujrathi, Sheila
    Hartung, Jeffrey P.
    Olson, Allan
    Cravets, Matt
    Frohna, Paul A.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 72 - 72
  • [26] Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
    Fazekas, F
    Deisenhammer, F
    StrasserFuchs, S
    Nahler, G
    Mamoli, B
    LANCET, 1997, 349 (9052): : 589 - 593
  • [27] The efficacy of cladribine in relapsing-remitting multiple sclerosis: Magnetic resonance imaging data from a randomized, double blind, placebo-controlled, 18-month, phase II trial
    Sipe, Jack C.
    Gardner, Jason
    Beutler, Ernest
    NEUROLOGY, 2008, 70 (11) : A105 - A105
  • [28] Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial
    Rahimlou, Mehran
    Nematollahi, Shima
    Husain, Durdana
    Banaei-Jahromi, Nasrin
    Majdinasab, Nastaran
    Hosseini, Seyed Ahmad
    FRONTIERS IN NEUROSCIENCE, 2022, 16
  • [29] Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome
    Millefiorini, E
    Gasperini, C
    Pozzilli, C
    DAndrea, F
    Bastianello, S
    Trojano, M
    Morino, S
    Morra, VB
    Bozzao, A
    Calo, A
    Bernini, ML
    Gambi, D
    Prencipe, M
    JOURNAL OF NEUROLOGY, 1997, 244 (03) : 153 - 159
  • [30] Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome
    E. Millefiorini
    C. Gasperini
    C. Pozzilli
    F. D’Andrea
    S. Bastianello
    M. Trojano
    S. Morino
    V. Brescia Morra
    A. Bozzao
    A. Calo’
    M. L. Bernini
    D. Gambi
    M. Prencipe
    Journal of Neurology, 1997, 244 : 153 - 159
12345